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Drugs and drug combinations have complex biolog-
ical effects on cells and organisms. Little is known
about how drugs affect protein dynamics that deter-
mine these effects. Here, we use a dynamic proteo-
mics approach to accurately follow 15 protein levels
in human cells in response to 13 different drugs. We
find that protein dynamics in response to combina-
tions of drugs are described accurately by a linear
superposition (weighted sum) of their response to
individual drugs. The weights in this superposition
describe the relative impact of each drug on each
protein. Using these weights, we show that one can
predict the dynamics in a three-drug or four-drug
combination on the basis of the dynamics in drug
pairs. Our approach might eliminate the need to
increase the number of experiments exponentially
with the number of drugs and suggests that it might
be possible to rationally control protein dynamics
with specific drug combinations.
INTRODUCTION
Drug combinations are thought to be essential to treat multi-
factor diseases (Berenbaum, 1989; Greco et al., 1995; Keith
et al., 2005). Much is known about the way drugs combine to
affect biological outcome, such as cell death or proliferation
(Leha´r et al., 2007). Drug interaction experiments show synergy,
independence, or antagonism of drug effects and are compared
to classical pharmacological models such as Bliss indepen-
dence (Bliss, 1939), Loewe additivity (Loewe, 1953), and more
elaborate functions (Fitzgerald et al., 2006; Potti et al., 2006;
Yeh et al., 2006; Garman et al., 2007; Leha´r et al., 2007). The
experimental study of multidrug combinations poses a well-
known combinatorial problem, since the number of experiments
grows exponentially with the number of drugs and doses
measured.
Whereas drug effects on outcome are much studied, the effect
of drug combinations on protein dynamics in the cell is much less
investigated. Understanding the impact of drugs on each proteinis important in the context of a vision of a future medicine that
controls protein dynamics precisely, using specific combina-
tions of a large number of drugs. Imagine that the cell state
can be described in a high dimensional space in which each
axis is the level (or localization or activity) of one of the cells
proteins (Figure 1). The goal is to guide the cell from a ‘‘sick
state’’ to a ‘‘healthy state’’ in a rational manner (or, in the case
of cancer, from a living cancer cell to a dead or quiescent cancer
cell). This entails understanding the dynamical response of each
protein to each drug at each dose, in the context of all possible
combinations of the other drugs. To approach such rational
control requires study of the degree to which protein dynamics
in drug combinations can be understood.
To address this, we use a dynamic proteomics approach
(Sigal et al., 2006; Cohen et al., 2008) to follow the dynamics of
the expression level of a panel of proteins in individual living
human cells at high temporal resolution and accuracy, as they
respond to combinations of 13 drugs, including chemothera-
peutic drugs, specific pathway inhibitors, and growth factors.
We find that the dynamics of each protein in the presence of
a drug combination is described accurately by a linear superpo-
sition (weighted sum) of the dynamics in the presence of each
drug alone. The weights in this superposition are constant over
time and depend on the drug dose. They describe the relative
impact of each drug on each protein. We find that one can
predict the dynamics in a multidrug combination on the basis
of the dynamics in pairs of drugs. Extending this approach
may allow understanding the vast space of multidrug and
multidose combinations based on a relatively small number of
two-drug measurements.RESULTS
System for Measuring Protein Dynamics in Living Cells
To follow proteins in space and time in individual living cells, we
used a dynamic proteomics approach (Sigal et al., 2006; Cohen
et al., 2008). We employed a library of cell line clones, based on
the H1299 human lung cancer cell line. In each clone, a different
protein is tagged with yellow fluorescent protein (YFP), inserted
as an exon in the chromosomal locus of the gene. The clone
expresses a full-length fusion protein from its native chromo-
somal location under its endogenous regulation. ImmunoblotsCell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc. 643
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Figure 1. Schema for Rational Control of Cell State
Uses drug combinations to move cells from protein state A to protein state B.
Each axis represents the level, location, modification or activity of one protein
(or other component or process). In this study, we focus on protein level
(expression) dynamics. Only two axes are drawn, out of the many thousands
representing all cell proteins.on a subset of these clones indicated that 80% of the tagged
proteins serve as accurate markers for the dynamics of the
endogenous protein (Cohen et al., 2008). The present library
includes about 1400 different tagged proteins. The clones are
all tagged with a second red fluorescent marker that enables
automated image analysis (Cohen et al., 2008).
For this study, we selected 15 proteins that represent different
aspects of cell biology (see Table S3, part a, available online).Table 1. Summary of Survival after Chemotherapy Drug Combinatio
Combination Dose (mM) Survivala (Measu
CPT 0.33 0.75 (±0.04)d
CPT 0.01 0.95 (±0.11)
CisPt 80 0.90 (±0.15)
CisPt 800 0.52 (±0.08)
CisPt 0.8 1.00 (±0.10)
NCZ 1 0.47 (±0.06)
Etopo 100 0.29 (±0.03)
CPT/CisPt 0.33/80 0.68 (±0.08)
CPT/CisPt 0.33/800 0.20 (±0.02)
CPT/NCZ 0.33/1 0.80 (±0.10)
NCZ/CisPt 1/80 0.73 (±0.07)
NCZ/CisPt 1/800 0.37 (±0.02)
Etopo /CPT 100/0.33 0.08 (±0.02)
Etopo /CisPt 100/80 0.27 (±0.02)
Etopo /NCZ 100/1 0.44 (±0.06)
CPT/NCZ/CisPt 0.33/1/80 0.69 (±0.09)
CPT/CisPt/Etopo 0.33/80/100 0.08 (±0.02)
CPT/NCZ/CisPt/Etopo 0.33/1/80/100 0.10 (±0.06)
See also Figure S6.
a Surviving cells in response to the indicated drugs and their combinations a
b The predicted survival based on Bliss independent model (see the main te
c Synergism is defined when the actual measured number of viable cells is lo
when measured and Bliss viability match within their errors.
d Standard errors from six repeats are numbers in parentheses.
644 Cell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc.These include representatives from systems such as the ribo-
some, oxidative stress, DNA repair, metabolism, cytoskeleton,
and apoptosis. The proteins localize to different cell compart-
ments, including the nucleus, cytoplasm, and nucleoli. The
dynamics of each protein in the presence of drugs was moni-
tored by time-lapse microscopy under incubated conditions in
multi-well plates as described in Cohen et al. (2008) (see the
Experimental Procedures). Dynamics of the fluorescence of
tagged protein for each cell was obtained by automated image
analysis. The dynamics presented are the average of 200–400
individual cell dynamical profiles, taken from two to four
repeated movies with four fields of view in the same well for
each movie. Day-day reproducibility of the dynamics was better
than 10% (RMS error).
Proteins Show Different Dynamics under Each Drug
We chose 13 drugs including chemotherapy agents, pathway
inhibitors, and growth factors (Table S3, part b). These drugs
have diverse antagonistic or synergistic interactions when
assayed for cell death using neutral red (Table 1). For example,
etoposide (ETOPO) combined with camptothecin (CPT) shows
synergism, in the sense of enhanced cell killing relative to Bliss
independence (in which each drug kills a fraction of the cells
independently of the other). In contrast, ETOPO combined with
Nocodazole (NCZ) shows reduced killing (antagonism).
We tested the dynamics of the 15 proteins with these drugs at
equi-lethal concentrations (for some drugs, only a subset of the
proteins was tested). We find that each protein shows differentn Treatment
red) Survivalb (Bliss Independence) Interactionc
* *
* *
* *
* *
* *
* *
* *
0.68 (±0.12) additive
0.39 (±0.06) synergistic
0.35 (±0.05) antagonistic
0.42 (±0.09) antagonistic
0.24 (±0.05) antagonistic
0.22 (±0.03) synergistic
0.27 (±0.05) additive
0.14 (±0.02) antagonistic
0.32 (±0.07) antagonistic
0.20 (±0.04) synergistic
0.09 (±0.02) additive
s was measured by neutral red assay (see the Experimental Procedures).
xt).
wer than the Bliss model. Antagonism is for the opposite, and additive is
Figure 2. Protein Dynamics in Drug Combinations Can Be Described as a Linear Superposition of the Dynamics under Single Drugs Applied
Separately
(A) Proteins respond differently to each drug. Shown are protein fluorescence levels as a function of time after the addition of drugs at time t = 0. Protein
fluorescence levels P(t) are normalized to initial level at time of drug addition P(0), as follows (P(t)-P(0))/P(0). Ribosomal protein RPS3 (1), nuclear lamina protein
LMNA (2), TOP1 (3), and Ka1 (alpha tubulin) with 0.33 mM CPT (blue) and 1 mM NCZ (red) (4) are shown. Error bars represent the standard errors of three or more
independent experimental repeats.
(B) Dynamics in drug pair is a linear superposition of the dynamics in each drug alone. Shown are same proteins and drugs as in (A). Dynamics in the presence of
both drugs is in purple. The linear superposition is in light blue. Error bars represent the standard errors of three or more independent experimental repeats.
(C) Dynamics in drug pair is a linear superposition of the dynamics in each drug alone. Proteins and drug combinations are indicated. Dynamics in the presence of
both drugs is in purple, linear superposition is in light blue. Error bars represent the standard errors of three or more independent experimental repeats.
See also Figures S1, S2, S3, and S4 and Tables S1 and S2.dynamics for each drug. For example, ribosomal protein RPS3
levels rise under NCZ, but decrease under CPT (Figure 2A,
part 1). Thus, drugs that all result in cell death still have different
effects on each of the proteins (Figure 2A).
Dynamics under Two-Drug Combinations
Is a Linear Superposition of Single-Drug Dynamics
We next tested the dynamics of the 15-protein panel in combina-
tions of drug pairs. Here, we mixed together the same doses as
used for the single-drug dynamics. We tested a total of 19
combinations of the 13 drugs. We find that in 12 of the 13 drugs
(the exception is PI3K inhibitor, discussed below) the dynamics
in drug pairs can be described to within experimental error bya weighted sum of the dynamics in the presence of each drug
alone (Figures 2B and 2C). Thus,
Pi+ jðtÞ=wi PiðtÞ+wj PjðtÞ:
Here, Pi+j is the protein level in the combination of drugs i and j,
Pi and Pj are the levels in each drug alone. Protein levels are
normalized to the initial protein level before the drugs are added,
P(t) = (P(t)-P(0))/P(0). Note that the weights wi and wj are constant
over time. In other words, measurement of each drug alone, and
the combination at a single time point to estimate the two
weights wi and wj, is enough to predict the dynamics of the
combination at all time points in the experiment.Cell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc. 645
Figure 3. The Linear Superposition Weights
Are Specific to Each Protein, Indicate Domi-
nance of Drugs, and Increase with Drug
Dose
(A) Weights indicate effect of each drug for each
protein. Shown are weights (blue for CPT 0.33
mM and red for NCZ 1 mM) for proteins in the
combination of CPT and NCZ (1). CPT dominates
NCZ for most proteins (DDX18 is an exception).
Weights (blue for CPT 0.33 mM and red for CisPt
80 mM) for proteins in the combination of CPT
and CisPt are shown in (2). CPT dominates CisPt
for most proteins. Error bars are the 95% confi-
dence range of linear fit. (3) shows a histogram of
the sum of weights of individual proteins in all
experiments is centered around 1.
(B) Weights for a given drug increase with its dose.
(1) and (2) show the mean weight over different
proteins at different CPT concentrations and at a
constant NCZ concentration of 1 mM (1) and a
constant CisPt concentration of 80 mM (2). Error
bars represent the STDs of the weights of different
proteins. The solid line is a Hill function with n = 1 ±
0.6 and K = 7 ± 5 nM (1), and n = 0.5 ± 0.3 and
K = 15 ± 7 nM (2). Error bars indicate standard
errors. Weights for LMNA as a function of the
doses of CisPt and CPT are shown in (3). The CisPt
weight is shown, which increases with CisPt dose
and decreases with CPT dose. This is well fit as
a product of two Hill-like functions one increasing
with with n1 = 8 ± 7, K1 = 85 ± 7 mM, and the other
decreasing with n2 = 1 ± 0.7 and K2 = 2 ± 2 mM (4).
See also Figures S3, S4, and S5 and Table S2.The weights are specific for each protein (Figure 3A, parts 1
and 2), and in most cases they add up to approximately one:
wi + wj  1 (Figure 3A, part 3). Thus, the dynamics in the present
two-drug combinations tend to lie between the dynamical curves
of each drug alone, similar to a weighted average of the two
curves. Such superposition is somewhat surprising. In principle,
one may have expected other effects; for example, a protein re-
sponse that exceeds both single drug responses, such as would
result if the two dynamics were purely additive (with wi = wj = 1).
As a statistical test of the superposition phenomenon, we per-
formed a data shuffling test. In this test, we attempted to
describe the dynamics of a protein in two-drug combinations
by means of a weighted sum of the single drug dynamics of other646 Cell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc.proteins (Figure S1). We find that the error
of the best-fit superposition in this shuf-
fling approach is always higher than the
error that results when describing each
protein as a superposition of its own
single-drug dynamic profiles (p < 0.001).
As a further test, we used principle
component analysis (PCA) (Pearson,
1901; Jolliffe, 2002) to ask to what extent
the two-drug dynamics are a linear
combination of the single-drug dynamics.
If the measured combination Pi+j is a pure
linear combination of the individual-drugdynamics Pi, Pj, then PCA over the three vectors Pi, Pj, and Pi+j
would result in only two components that are larger than zero
and a third component that is equal to zero. Application of
PCA to all 15 proteins results in 99.5% of the variability in the
two first principle components, leaving only a 0.5% effect not
explained by linear superposition (Figures S1A–S1F).
Some trends in the weights can be seen, where certain drugs
seem to have larger weights than others. We find that the weights
for CPT for most proteins are larger than those for NCZ and
similarly larger than the weights for CisPt (Figure 3A, parts 1
and 2). This means that the combination of either NCZ or CisPt
with CPT at the present doses leads to dynamics that are domi-
nated by CPT. In particular, the CPT drug target, TOP1, shows
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Figure 4. The PI3-Kinase Inhibitor, PI3KI, Does Not Show Linear
Superposition
Dynamics of TOP1 in the combinations CPT (0.33 mM) and PI3KI (0.1 mM) (A)
and MG132 (1 mM) and PI3KI (0.1 mM) (B) are not well described by a linear
superposition (best fit linear superposition is in light blue). Error bars represent
the standard errors of three or more independent experimental repeats.
See also Table S1.dynamics completely dominated by CPT, with weight close to
one for CPT and nearly zero for the other drug in the pair. The
dominance of CPT does not apply however to all proteins: an
exception is the protein DDX18, in which NCZ dominates CPT.
This may point to the pathway-specific impact of each drug.
Overall, about 20% of the cases we tested showed strong
dominance by one drug in a drug pair (three out of 15 cases
showed dynamics more than 90% dominated by one of the
two drugs).
Weights for Each Drug Increase with Drug Dose
We also tested the effects of varying the drug dose. We find that
the linear superposition principle applies across drug concentra-
tions. The resulting weights for a given drug are an increasing
function of its dose (Figure 3B, parts 1 and 2). For example,
when CPT levels are reduced from 330 nM to 3.3 nM, it is no
longer dominant over NCZ for most proteins. The weights asa function of dose x are reasonably described by Hill-like func-
tions, wi(x) = wmax x
n/(Kn+xn). The halfway point K depends on
the dose of the other drug in the pair.
We extensively tested the superposition hypothesis in the
case of the protein LMNA, in 96 different dose combinations of
CPT and CisPt, using a 96-well assay in the microscope. We
find that linear superposition accurately describes the dynamics
in all dose combinations. The weights in each dose combination
can be represented in a two-dimensional map (Figure 3B, part 3),
and are well fit by the product of two Hill-like functions
(Figure 3B, part 4). Thus, the weight for CisPt in the presence
of CPT is w1(x,y) = h1(x)$h2(y), where x is the CisPt dose and
y is the CPT dose. Here, h1 is a Hill functions of x,
h1ðxÞ= xn1=xn1 +Kn11 , and h2 is a decreasing Hill function of y,
h2ðyÞ=Kn22 =yn2 +Kn22 . Similar findings were obtained with 96
combinations of CPT and NCZ.
No Linear Superposition Is Found with PI3K Inhibitor
One drug does not seem to show linear superposition with other
drugs, the PI3K inhibitor, Wortmanin. Addition of this compound
to other drugs seems to result in dynamics that can not be well
described as a weighted sum of the two single-drug dynamics
(Figures 4A and 4B). We could not find a compelling reason
why this drug behaves differently from the others in the present
study.
Adding a Drug to Itself
An additional test case is when a drug is combined with itself.
This can be considered as a limiting case in which the two drugs
in a cocktail are one and the same. One can imagine situations
where, for example, the dynamical profile of a drug at dose x is
not a weighted sum of its two dynamical curves at dose x/2.
We tested this for three of the drugs, CPT, ETOPO, and CisPt.
We find that for most concentrations, linear superposition holds
to excellent approximation even when adding a drug to itself
(Table S1 and Figure S2).
Linear superposition can be mathematically shown to hold
true when adding a drug to itself, if the drug has a dose response
that can be separated into a product of a dose-dependent
function and a time-dependent one, in the following way:
P(D,t) = h1(t)+ h2(t)$ g(D), where D is the dose and t the time
(see the Extended Results, ‘‘Adding a Drug to Itself’’). The drugs
presently tested seem to have a dose-response that shows
such a separability feature. It is conceivable, however, that other
drugs have a nonseparable interplay between dose and
temporal response profiles, so that linear superposition of the
drug with itself will not hold.
Dynamics in Three-Drug and Four-Drug Combinations
Can Be Predicted on the Basis of Two-Drug Dynamics
We next tested combinations of three drugs, CPT (0.33 mM) +
CisPt (80 mM) + NCZ (1 mM) (Table S1) and CPT (0.3 mM) + CisPt
(80 mM) + ETOPO (100 mM) (Figure 5A and Table S1), and a
combination of all four drugs CPT (0.33 mM) + CisPt (80 mM) +
ETOPO (100 mM) + NCZ (1 mM) (Figure 5B and Table S1). We
find that, as in the two-drug case, the dynamics are a linear
superposition of the single-drug dynamics. Superposition
captures multidrug dynamics extremely well (the fit lies withinCell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc. 647
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Figure 5. Dynamics in Three-Drug and
Four-Drug Combinations Can Be Predicted
on the Basis of Two-Drug Dynamics
(A) Dynamics in a combination of three drugs is a
linear superposition of single-drug dynamics and
can be predicted based on two-drug weights.
Dynamics of TOP1 under CPT (0.33 mM) (blue),
CisPt (80 mM) (red) and ETOPO (100 mM) (green),
and in a combination of all three (purple), is well
described by a linear superposition (light blue)
and by the estimated response on the basis of
two-drug combination (orange) (1). Error bars
represent the standard errors of three or more
independent experimental repeats. Best-fit (gray)
and predicted (black) weights of CPT (2), CisPt (3),
and ETOPO (4) for the proteins are shown. Error
bars are the 95% confidence range of linear fit.
Dynamics for all proteins tested is shown in Table
S1. See also Figure S5.
(B) Dynamics in a combination of four drugs is a
linear superposition of single drug dynamics and
can be predicted on the basis of two-drug
weights. Dynamics of TOP1 under CPT (0.33
mM) treatment (blue), NCZ (1 mM) (red), CisPt (80
mM) (green), ETOPO (100 mM) (dark green), and
in a combination of all four (purple) is well
described by a linear superposition (light blue)
and by the estimated response based on two-
drug combination (orange) are shown in (1). Error
bars represent the standard errors of three or
more independent experimental repeats. Best-fit
(gray) and predicted (black) weights of CPT (2),
NCZ (3), CisPt (4), and ETOPO (5) for individual
proteins are shown. Error bars are the 95% confi-
dence of linear fitting. See also Table S1.the bounds of the experimental error) and is highly significant
in data shuffling tests (p < 104). The weights are again specific
to each protein and sum up to approximately one.
We hypothesized that the three-drug weights can be pre-
dicted based on the two-drug weights. To see this, note648 Cell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc.that if the linear superposition principle
holds for three drugs
Pi+ j+ k =w
ðijkÞ
i Pi +w
ðijkÞ
j Pj +w
ðijkÞ
k Pk
and for each of the three different pair
combinations
Pi+ j =w
ðijÞ
i Pi +w
ðijÞ
j Pj;
then one has enough equations to solve for
the three-drug weights on the basis of the
two-drug weights (see the Extended
Results, ‘‘Derivation of the Prediction
Equations for Three and More Drugs,’’
andTable S1).Here,wi
ijdenotes the weight
ofdrug i in the presenceofdrugs i+j, and for
the purpose of the present calculation
weights are normalized to sum up to one.The resulting formula for three-drug weights based on the two-
drug weights is
w
ðijkÞ
i =
w
ðikÞ
i wðikÞi wðjkÞj
1 wðikÞi wðjkÞj
:
The same reasoning can be extended to four drugs and
more. The corresponding formula for N-drug weights based on
(N1)-drug weights is
w
ð1::NÞ
i =
w
ðsjÞ
i wðsjÞi wðsiÞj
1 wðsjÞi wðsiÞj
;
where (sj) means all drugs but j. This results in one equation for
each choice of jsi, a total of N1 equations. These equations
can be solved starting from two-drug weights until one reaches
N-drug weights. We estimated the weights in the four-drug
combinations by averaging over the predictions given by these
equations. We find that the predicted weights agree very well
with the best-fit weights for most proteins (Figure 5 and Fig-
ure S5): correlation between best-fit and predicted weights is
R = 0.92, p < 1015. Thus, knowledge of two-drug weights seems
to provide a good estimate for dynamics in three- and four-drug
combinations.
DISCUSSION
We studied the effects of drug combinations on the dynamics of
endogenously tagged proteins in living human cells. We find that
each protein responds differently to each drug. The protein
dynamics under a combination of drugs is well described in
most cases by a linear superposition (a weighted sum) of the
dynamics under each drug alone. The weights are specific to
each protein and are dose dependent and constant over time.
They tend to sum up to approximately one. The linear superposi-
tion principle seems to carry over also to three- and four-drug
combinations, where the dynamics can be predicted on the basis
of two-drug measurements. This suggests that, at least for these
drugs and cells, protein level dynamics might be rationally
controllable on the basis of a simple superposition principle.
The present approach offers a way to bypass the combinato-
rial explosion problem of research on drug combinations. If
drugs interacted to affect protein levels in a complex nonlinear
way, one would need a separate experiment to understand
each drug-dose combination. Thus, to explore all possible
combinations requires a number of experiments that grows
exponentially with the number of drugs and doses. A potential
way to bypass this challenge lies in the finding that three- and
four-drug dynamics can be predicted on the basis of two-drug
dynamics. If this may be extended to other proteins, drugs and
cells, the present approach can reduce the combinatorial explo-
sion problem inherent in understanding multidrug combinations.
To make this reasoning explicit, note that measurement of all
combinations of N drugs at k dose levels requires kN experi-
ments. In contrast, measurement of single and double drug
mixes requires far fewer experiments, k2N(N-1)/2+Nk. For N = 10
drugs and k = 8 doses, this means about 109 experiments for all
combinations, and only about 3000 measurements (31 96-well
experiments) to cover all single-drug and drug-pair dynamics.
To measure all combinations of 100 drugs, each either present
or absent in a cocktail, requires 21001030 experiments, but
only about 5000 experiments to cover all pairs.
Thus, if the superposition principle applies beyond the present
system, relatively few drug-pair measurements may allow one tocomputationally navigate the high-dimensional space of drugs
and doses and to find an optimal drug cocktail (Jonker et al.,
2005). It is expected that the predictions will only be approxi-
mate, but they can serve as a guide to relevant regions of
drug-dose space that would otherwise be prohibitively difficult
to find.
Why are the effects of drugs on protein dynamics linearly
superposable? Why does a small set of constants, the weights,
describe the relations between single- and multiple-drug
behavior at all time points? This is a fascinating avenue for future
research. One way to obtain such linear superposition is by
describing protein responses as a linear perturbation around
the steady-state of a nonlinear system (Strogatz, 2001; Thattai
and van Oudenaarden, 2001; Tegner et al., 2003; Prill et al.,
2005). This does not seem to explain most of the cases consid-
ered in this study, because linear perturbations apply only to
small variations, whereas the present experiments show rather
large dynamical movements.
Future work can test when superposition holds and breaks
down, and, more generally, how the structure of cell circuits
(Alon, 2006) affects protein dynamics in response to drugs and
drug combinations. (di Bernardo et al., 2005; Leha´r et al.,
2007). At present, we do not have a mechanistic explanation
for superposition. Further experimental and theoretical work
will be required to answer such questions.
We hope that the present study is a step in the direction of a
future medicine that produces precise biological outcome by
rationally controlling the dynamics of proteins in cells. Drug
combinations based on the superposition principle can perhaps
aim toward alleviating unwanted side effects (using drugs to
cancel out each other’s unwanted effects on specific proteins),
and improving efficacy.
EXPERIMENTAL PROCEDURES
Fluorescently Tagged Protein Clones
All clones in this study are from the LARC library, in which proteins were
fluorescently tagged in their endogenous chromosomal locus under their
endogenous regulation, by CD tagging, as described (Sigal et al., 2006; Sigal
et al., 2007; Cohen et al., 2008). Clones are based on H1299 non-small-cell
lung carcinoma cells and were described Cohen et al. (2008).
Tissue Culture Media
Cells were grown in RPMI 1640 supplied with (+) L-Glutamine (GIBCO, catalog
number 21875) medium supplemented with 10% Fetal Calf Serum (certified
fetal bovine serum, membrane filtered, Biological Industries, catalog number
04-001-1A) and 0.05% Penicillin-Streptomycin antibiotics (Biological Indus-
tries, catalog number 03-031-1B). Cells were grown in incubators at 37C
and 8% CO2.
Drugs
Cisplatinum (P4394 Sigma) was dissolved in DMSO (hybri-max, D2650 Sigma)
giving a stock solution of 100 mM; Nocodazole (M1404, Sigma) was dissolved
in DMSO giving a stock solution of 33.2 mM; and Camptothecin (CPT, C9911
Sigma) and Etoposide (E1383 Sigma) were dissolved in DMSO giving a stock
solution of 10 mM. Human recombinant EGF was reconstituted in 10 mM
acetic acid containing 0.1% BSA to a final concentration of 10 mg/ml; HGF
(Calbiochem, catalog number 375228) was dissolved in sterile PBS to a final
concentration of 2 mg/ml (26.7 nM). MAPK inhibitor (U0126, Calbiochem,
catalog number 662005) was dissolved in DMSO to a final concentration of
5 mM. In each experiment, drug was diluted to the desired concentration inCell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc. 649
transparent growth medium (RPMI 1640, 0.05% Penicillin-Streptomycin
antibiotics, 10% FCS, with L-Glutamine, lacking riboflavin and phenol red,
Bet Haemek, Biological Industries, catalog number 06-1100-26-1A). Normal
transparent growth medium (2 ml, without the drug) was replaced by the
diluted drug (2 ml medium with the final desired concentration of each drug)
under the microscope after at least one round of images without the drug (at
least one image per each field of view was taken before drug addition).
Viability Assay
Cell viability was determined by neutral red accumulation (Fluka Chemie,
catalog number 72210, Buchs, Switzerland), (Zhang et al., 1990) as follows:
after 48 hr incubation (37C, 8% CO2) with drugs (or no drugs as control),
100 ml neutral red reagent (diluted 1:100 in growth medium) was added to cells
for 35 min incubation. Neutral red buffer was washed and fixation buffer (1%
CaCl2, 0.5% formaldehyde) was added. For extraction of the remaining cells,
extraction buffer (1% glacial acetic acid, 50% ethanol) was added. Cells were
shaken for 10 s, and optical density (570 nm) was read by an ELISA reader
(BIO-RAD Model 680 Microplate Reader). After subtraction of assay blanks
(wells with no cells), net optical density was computed as the average value
of six replicate determinations. Cell survival was calculated as the percentage
of the dye accumulated in the untreated controls.
Time-Lapse Microscopy
Time-lapse movies were obtained at 203 magnification. Four automated
microscopes were used, three inverted fluorescence microscopes from Leica
(DMIRE2 and DMI6000B) and one from Olympus (modified IX71). All
microscopes included live-cell environmental incubators maintaining 37C
(37-2 digital and Heating unit, PeCon, Germany, Leica #15531719) humidity
and 8% CO2 (PeCon, Germany #0506.000-230, Leica #11521733) and
automated stage movement control (Corvus, ITK, Germany); the stage was
surrounded by a custom enclosure to maintain constant temperature, CO2
concentration, and humidity. Transmitted and fluorescence light paths were
controlled by electronic shutters (Uniblitz, model VMM-D1, Rochester, NY);
fluorescent light sources were Mercury short arc lamp HXP and Mercury
HBO100 (OSRAM, Germany). Cooled 12 and 14 bit CCD cameras were
used, QImaging, (RETIGA-S&V, Fast 1394, RET-SRV-F-M-12-C, Canada),
CoolSNAP (Roper Scientific HQ, photometrics), ORCA-ER (C4742-95-
12ERG, Hamamatsu photonics K.K, Japan), and iXon (Andor technology).
The filters used were from Chroma Technology: on the Leica systems, single-
channel filters were YFP (500/20 nm excitation, 515 nm dichroic splitter, and
535/30 nm emission, Chroma #41028) and mCherry Red (575/50 nm excitation,
610 nm dichroic splitter, and 640/50nm emission, Chroma #41043) and on the
Olympus Dual channel dichroic with excitation and emission filters mounted on
fast filter wheels (Chroma set 490/20x, 577/25x, 535/30 m, 632/60 m). The
Leica system hardware was controlled by ImagePro5 Plus software (Media
Cybernetics), which integrated time-lapse acquisition, stage movement, and
software-based autofocus (adjusted in our lab). The Olympus system integra-
tion and fast laser autofocus was from Idea Bio-Medical (Rehovot, Israel).
Cells were grown and visualized in 12-well optical glass-bottom plates (Mat-
Tek cultureware, Microwell plates-uncoated, part number P12G-0-14-F, lot
number TK0289) or optical bottom 96-well plates (Nunc, 164588), both coated
with 10 mM fibronectin 0.1% (solution from bovine plasma, Sigma, catalog
number F1141) diluted 1:100 in Dulbecco’s phosphate-buffered saline (PBS;
Sigma, catalog number D8537). In order to reduce background fluorescence,
cells were grown in RPMI 1640 lacking riboflavin and phenol red (Beit Haemek,
Biological Industries, catalog number 06-1100-26-1A) supplemented with
L-Glutamine, 10% fetal calf serum (certified fetal bovine serum, membrane
filtered, Biological Industries, 04-001-1A), and 0.05% Penicillin-Streptomycin
antibiotics (Biological Industries, catalog number 03-031-1B). For each well,
time-lapse movies were obtained at four fields of view. Each movie was taken
at a time resolution of 20 min and was filmed for at least 2 days (over 140 time
points). Each time point included transmitted light image (phase contrast) and
two fluorescent channels (red and yellow).
Image Analysis of Time-Lapse Movies
We used the image analysis software described in Cohen et al. (2008).
The main steps in this software include background correction (flat field and650 Cell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc.background subtraction), segmentation, cell tracking, and automated identifi-
cation of cell phenotypes (mitosis and cell death). No significant bleaching was
observed (on average less than 3% over the duration of the experiment). Cell
and nuclei segmentation was based on the red fluorescent images of the red
tagged protein found in all clones, localized to the cytoplasm and nucleus, with
intensity which is very uniform across cells and clones. Segmentation used
global image threshold (Otsu, 1979) and seeded watershed segmentation.
Seeds were obtained by smoothening of the red intensity image and use of
nuclei as cell seeds. Tracking was performed by analysis of the movie from
end to start and linking of each segmented cell to the cell in the previous image
with the closest centroid. Automated cell death identification algorithm utilized
the morphological changes correlated with dying cells.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Results, six figures, and three
tablesand can be found with this articleonline at doi:10.1016/j.cell.2010.02.011.
ACKNOWLEDGMENTS
This work was supported by the Kahn Family Foundation and by Keren
Isra-Pa’amei Tikva. We thank Pierre Choukroun for assistance with the
computer cluster. We thank J. Lehar, W. Koestler, J. Bar, I. Glinert, Y. Aylon,
and all members of the Alon laboratory for fruitful discussions, comments,
and technical help.
Received: May 27, 2009
Revised: November 6, 2009
Accepted: February 4, 2010
Published: March 4, 2010
REFERENCES
Alon, U. (2006). An Introduction to Systems Biology: Design Principles of
Biological Circuits (London: Chapman & Hall/Crc).
Berenbaum, M.C. (1989). What is synergy? Pharmacol. Rev. 41, 93–141.
Bliss, C. (1939). The toxicity of poisons applied jointly. Ann. Appl. Biol. 26,
585–615.
Cohen, A.A., Geva-Zatorsky, N., Eden, E., Frenkel-Morgenstern, M., Issaeva,
I., Sigal, A., Milo, R., Cohen-Saidon, C., Liron, Y., Kam, Z., et al. (2008).
Dynamic proteomics of individual cancer cells in response to a drug. Science
322, 1511–1516.
di Bernardo, D., Thompson, M.J., Gardner, T.S., Chobot, S.E., Eastwood, E.L.,
Wojtovich, A.P., Elliott, S.J., Schaus, S.E., and Collins, J.J. (2005). Chemoge-
nomic profiling on a genome-wide scale using reverse-engineered gene
networks. Nat. Biotechnol. 23, 377–383.
Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B., and Sorger, P.K. (2006). Systems
biology and combination therapy in the quest for clinical efficacy. Nat. Chem.
Biol. 2, 458–466.
Garman, K.S., Nevins, J.R., and Potti, A. (2007). Genomic strategies for
personalized cancer therapy. Hum. Mol. Genet. 16 Spec No. 2, R226–R232.
Greco, W.R., Bravo, G., and Parsons, J.C. (1995). The search for synergy:
a critical review from a response surface perspective. Pharmacol. Rev. 47,
331–385.
Jolliffe, I.T. (2002). Principle Component Analysis (Aberdeen, UK: Springer
Series in Statistics).
Jonker, D.M., Visser, S.A., van der Graaf, P.H., Voskuyl, R.A., and Danhof, M.
(2005). Towards a mechanism-based analysis of pharmacodynamic drug-
drug interactions in vivo. Pharmacol. Ther. 106, 1–18.
Keith, C.T., Borisy, A.A., and Stockwell, B.R. (2005). Multicomponent
therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71–78.
Leha´r, J., Zimmermann, G.R., Krueger, A.S., Molnar, R.A., Ledell, J.T., Heilbut,
A.M., Short, G.F., 3rd, Giusti, L.C., Nolan, G.P., Magid, O.A., et al. (2007).
Chemical combination effects predict connectivity in biological systems. Mol.
Syst. Biol. 3, 80.
Loewe, S. (1953). The problem of synergism and antagonism of combined
drugs. Arzneimittelforschung 3, 285–290.
Otsu, N. (1979). A threshold selection method from gray-level histograms. IEEE
Trans. Syst. Man Cybern. 9, 62–66.
Pearson, K. (1901). On lines and planes of closest fit to systems of points in
space. Philos. Mag. 2, 559–572.
Potti, A., Dressman, H.K., Bild, A., Riedel, R.F., Chan, G., Sayer, R., Cragun, J.,
Cottrill, H., Kelley, M.J., Petersen, R., et al. (2006). Genomic signatures to
guide the use of chemotherapeutics. Nat. Med. 12, 1294–1300.
Prill, R.J., Iglesias, P.A., and Levchenko, A. (2005). Dynamic properties of
network motifs contribute tobiological networkorganization. PLoSBiol.3, e343.
Sigal, A., Milo, R., Cohen, A., Geva-Zatorsky, N., Klein, Y., Alaluf, I., Swerdlin,
N., Perzov, N., Danon, T., Liron, Y., et al. (2006). Dynamic proteomics in
individual human cells uncovers widespread cell-cycle dependence of nuclear
proteins. Nat. Methods 3, 525–531.Sigal, A., Danon, T., Cohen, A., Milo, R., Geva-Zatorsky, N., Lustig, G., Liron,
Y., Alon, U., and Perzov, N. (2007). Generation of a fluorescently labeled
endogenous protein library in living human cells. Nat. Protoc. 2, 1515–1527.
Strogatz, S.H. (2001). Nonlinear Dynamics and Chaos: With Applications to
Physics, Biology, Chemistry, and Engineering (Cambridge, MA: Westview
Press).
Tegner, J., Yeung, M.K., Hasty, J., and Collins, J.J. (2003). Reverse engi-
neering gene networks: integrating genetic perturbations with dynamical
modeling. Proc. Natl. Acad. Sci. USA 100, 5944–5949.
Thattai, M., and van Oudenaarden, A. (2001). Intrinsic noise in gene regulatory
networks. Proc. Natl. Acad. Sci. USA 98, 8614–8619.
Yeh, P., Tschumi, A.I., and Kishony, R. (2006). Functional classification of
drugs by properties of their pairwise interactions. Nat. Genet. 38, 489–494.
Zhang, S.Z., Lipsky, M.M., Trump, B.F., and Hsu, I.C. (1990). Neutral red (NR)
assay for cell viability and xenobiotic-induced cytotoxicity in primary cultures
of human and rat hepatocytes. Cell Biol. Toxicol. 6, 219–234.Cell 140, 643–651, March 5, 2010 ª2010 Elsevier Inc. 651
